Although a dual GIP and GLP-1 receptor agonist has shown efficacy for glucose control and weight loss in clinical trials of patients with type 2 diabetes [6, 7], it is not clear how much of the observed effect is specifically attributable to GIP agonism. Here, GIP is linked to type 2 diabetes mellitus.